Stefan Evers (University of Münster, Germany), a valued member of our European editorial board, discusses the management of headache disorders with a focus on the new anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies.
Questions
1. What has our experience with ergotamine derivatives and triptans taught us about the pathophysiology of migraine? (0:04)
2. What is the rationale for targeting calcitonin gene-related peptide (CGRP) in the management of headache disorders? (0:43)
3. Which patients are most likely to respond to anti-CGRP monoclonal antibodies and in which patients should they not be used? (1:25)
4. What factors influence your choice of the currently available anti-CGRP monoclonal antibodies? (2:22)
5. What are the possible long-term safety concerns of anti-CGRP monoclonal antibodies? (3:01)
Speaker disclosure: Stefan Evers has nothing to disclose in relation to this video interview.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
